Breast Augmentation (Implants) | Risks and Complications

The decision is personal and benefits must be weighed against risks; consent forms ensure understanding. Implants may be saline or silicone gel, placed behind breast tissue, muscle or fascia, with incision choices depending on breast characteristics and preferences. Risks include anesthesia risks, BIA-ALCL or other very rare capsule cancers, hematoma, seroma, persistent pain, skin wrinkling, wrong implant position, and rare need for removal. Reoperation rates of 13-21% at 3 years and 20-26% at 5 years are reported, often for asymmetry, malposition, unsatisfactory size, ptosis, palpability or scarring. FDA-approved implants undergo extensive testing, and the vast majority of people with implants experience no serious complications; these risks and others are fully discussed before consent.

Capsular contracture means scar tissue around the implant firms and tightens; it is more often seen after placement above the chest muscle than below it. It is the most common long-term complication and can cause hardening, distortion and pain; it is the most common reason for reoperation, and recurrence can occur. Complications are mostly implant-related and may increase over time. Other problems include rupture or deflation, displacement, asymmetry, rippling, the implant being felt, infection, bleeding and nipple-area changes. Infection may sometimes require implant removal and later reinsertion. Rarely, implant-associated lymphoma, squamous cell carcinoma or systemic symptoms some patients attribute to implants are reported. Risks depend on implant type, anatomy and breast characteristics.

FDA-approved breast implants undergo extensive testing, and the vast majority of people with implants experience no serious complications. Still, possible risks include anesthesia risks, bleeding, infection, seroma, capsular contracture, implant leakage or rupture, sensation changes, poor scarring, wrong implant position, and very rare cancers in the capsule. Implants may be saline or silicone gel, and placement varies by patient. Breast augmentation can be carried out with breast implants or with the patient’s own fat, and incision placement depends on breast characteristics and surgeon and patient preferences. These risks and others are fully discussed before consent, and you will be asked to sign consent forms. Because it is major surgery, the result you hope for cannot be guaranteed.

Like any surgery, breast augmentation carries risks. Early problems can include bleeding, infection, wound breakdown, implant malposition or asymmetry; later problems can include capsular contracture, rippling, implant rupture or scarring. Capsular contracture, once reported at 20–30% and now about 5–6%, happens when the normal thin capsule around an implant thickens and tightens. It may begin at any time, even after years, but appears more often in early months and usually on one side. Rare but serious implant-associated conditions include BIA-ALCL, BIA-SCC and symptoms some patients attribute to breast implant illness. Careful planning and contamination-reduction techniques can reduce complications, but no result is guaranteed.

After implant placement, the body forms a capsule around it; normally this capsule stays thin and soft. In capsular contracture, chronic inflammation makes it thick, hard and shrink, altering contour and implant position. Breasts may become more spherical and implants may migrate upward, causing noticeable asymmetry. The capsule itself forms in every case, but problems arise when it tightens. Evidence links this to biofilm or bacterial contamination, blood, silicone gel leakage and tissue trauma, although the exact cause is not fully understood. Incidence varies by implant type and technique, estimated at 10–30% at five years. Prevention focuses on reducing bacterial contamination, minimizing tissue trauma and optimizing hemostasis.

Every implant is surrounded by a capsule of scar tissue. Capsular formation occurs in all cases, but contracture develops when that capsule tightens excessively, sometimes making the breast more rounded and uneven. Evidence links it to inflammation, including biofilm-related inflammation, and to factors such as infection, haematoma, seroma, implant position and time. Baker classification ranges from no contracture to painful contracture. A wide pocket and adequate fluid between wall and implant may help reduce risk . Reported rates vary by study and implant type, from about 8.1–18.9% in manufacturer core studies to up to 15% after primary augmentation and nearly 22% after revision in premarket studies; saline implants show 8–41% over ten years.

It is a common complication and is thought to arise from an exaggerated foreign-body response to chronic inflammation around the implant. The cause is not fully understood and is likely multifactorial. Prevention therefore focuses on reducing bacterial contamination, minimizing tissue trauma and controlling bleeding. Measures include intravenous antibiotic prophylaxis, careful atraumatic dissection, hemostasis, pocket irrigation, glove changes and minimizing implant handling time. A structured surgical plan, including the 14-point approach, can prevent capsular contracture in most patients, and the proven technique is felt by most to reduce risk to less than 2% for many patients. This is not a guarantee.

It happens when scar tissue thickens and tightens around the implant, often as a foreign-body response. Biofilm inflammation, especially Staphylococcus epidermidis, infection, hematoma, seroma, implant position and time can contribute. Breasts may become spherical, firm, painful or distorted, and implants may migrate upward. The capsule forms in all cases, but problematic tightening varies; severity varies widely between patients. Prevention focuses on reducing bacterial contamination, tissue trauma and bleeding. Capsular contracture is the most common complication after breast augmentation. It is a progressive phenomenon, and risk can increase over time. Patients may describe firm, hard breasts, pain, distortion or asymmetry. Treatment may involve capsulotomy, capsulectomy, implant plane change or revision with supportive material. No outcome can be guaranteed.

Capsular contracture is a common complication of breast augmentation, with incidence estimated at 10–30% at five years. It is thought to develop from an exaggerated foreign-body response to chronic inflammation around the implant. Early management may include manual displacement, massage, a leukotriene inhibitor such as Singulair, vitamin E, or external ultrasound, but evidence varies. Baker grades describe firmness and appearance from soft to hard and painful. Once contracture is well established, non-surgical treatment is less effective; surgery may involve removing the tight capsule, changing implant position, or replacing the implant, depending on severity, implant condition and your goals. Closed capsulotomy is now rarely indicated, and older series reported significant recurrence after it.

The body forms a fibrous capsule around the implant. Intracapsular rupture means the shell tears but gel stays within that capsule; extracapsular rupture means gel escapes into surrounding tissue, and it cannot happen without an intracapsular rupture first. Cohesive silicone usually does not spread, and silicone is not expected to cause systemic effects. Intracapsular rupture may be silent for years with little breast change, while extracapsular rupture can bring inflammation, lymph node changes or deformity and may need wider tissue removal. Palpable nodules, asymmetry, tenderness, contour change or a mass may suggest rupture. Both types require implant and gel removal.

Symptomatic silicone rupture can present with changes in breast size, shape or character, breast pain, palpable lumps in the breast or armpit, or new or worsening capsular contracture. However, many ruptures cause no symptoms, which is why routine screening is important. MRI is the most reliable test for silicone rupture, with reported sensitivity of 89% and specificity of 97%; ultrasound is another feasible option. Mammography and ultrasound may give useful clues, but they are less accurate for intracapsular rupture, especially at the rear wall. Silicone rupture may be intracapsular or extracapsular, and extracapsular rupture can involve silicone spread into surrounding tissues or lymph nodes. No test gives 100% certainty.

Intracapsular rupture means the shell breaks inside the fibrous capsule; gel usually stays confined, so volume may look unchanged and many patients are unaware. Extracapsular rupture means gel escapes into surrounding tissue and may cause inflammatory reaction, discomfort, palpable mass, lymph node changes or deformity. MRI is the best modality to assess silicone-gel implants for rupture, while mammography may show leakage. Rupture can follow shell weakening over time, operative damage, manufacturing flaw or breast injury. Intracapsular cases may remain asymptomatic for several years with little breast deformation, while extracapsular cases can follow serious trauma and may need wide tissue excision; MRI has high sensitivity and high specificity for diagnosis in validated studies.

Saline leaks through a small hole or valve failure, and most implants are fully deflated within the first 24 hours, although a small amount of saline may remain. This usually causes a noticeable change in breast size and shape, and the saline is harmlessly absorbed by surrounding tissues. The breast often reverts toward its original shape and position, with the upper border lower and the fold higher. Reoperation to remove the ruptured implant is recommended and may be combined with capsulotomy or capsulectomy, with or without replacement, depending on your preference and surgical discussion. The implant type, pocket plane, and access incision depend on discussions between surgeon and patient. Dr. Vishal Purohit can discuss options during consultation.

Implant rupture is listed among possible breast augmentation risks, and implants are not guaranteed to last a lifetime. Some ruptures cause symptoms, while others are silent, which is why regular breast health examinations and FDA-recommended MRI or ultrasound screening five to six years after silicone placement and every two to three years thereafter can help detect problems. If rupture is confirmed, the implant is removed and replaced with an intact implant. The exact risk and urgency depend on implant type, symptoms and imaging, so individual assessment matters. Silent rupture may still need planned review, and your surgeon can discuss whether symptoms, imaging findings or implant age change the timing of treatment.

Silent rupture is more common than symptomatic rupture. Because cohesive silicone gel can keep its shape after tearing, the breast may look unchanged at first, so changes can be subtle. Most ruptures are silent and detectable only by imaging such as MRI, the current gold standard; physical examination detects far fewer in practice. MRI is the most accurate way to assess silicone implant integrity, with about 89% sensitivity versus about 30% for physical examination. Implant rupture risk rises with time; implants are not lifetime devices. If silicone spreads outside the capsule, later problems such as capsular contracture, deformity, pain or nodularity may occur. The true incidence of silent rupture remains unknown.

Intracapsular ruptures can stay asymptomatic for several years with little breast deformation, while extracapsular ruptures may follow serious trauma and cause inflammatory changes. Ruptures can occur if the shell weakens, the implant is damaged, there is a flaw, or the breast is injured. MRI is the most reliable diagnostic tool, with reported sensitivity of 89% and specificity of 97%; physical examination detects only about 30% of MRI-detected ruptures. FDA guidance recommends screening five to six years after silicone implant placement and every two to three years thereafter. Holmich et al. estimated about 2% and 15% of third-generation implants intact after 3 years develop definite ruptures by 5 and 10 years.

Mild displacement may be managed conservatively with a modeling bra and elastic bands, while more severe or long-term cases may need reoperation to reshape the pocket with extra dissection or sutures. Anatomic implants can rotate when initially placed rotated or when seroma forms; sometimes a hidden seroma and double capsule contribute. Saline implants may be more likely to displace over time because of a water-hammer effect, and releasing inframammary fold fibers may increase that risk. Poor pocket dissection or implant pressure on the capsule may also contribute. Displacement exercises are generally recommended for smooth, round implants only, not textured or shaped devices.

Displacement may occur when pocket dissection is inaccurate or too extensive, when an implant is too large for the tissues, or when muscle pressure, trauma, rupture or capsular contracture changes its position. Anatomic implants can rotate if initially placed rotated or if seroma forms. Gland displacement can also follow a small haematoma or seroma, or a retromuscular implant that does not adequately fill a drooping breast. The implant may sit too high, too low, too medial or too lateral, and muscle movement or lower-pole stretching can alter appearance. Careful planning aims to reduce this risk. Preoperative asymmetry and implant rotation can also contribute. Discussing implant size and pocket choice helps set expectations.

It can be precipitated by technical error, poor planning, inappropriate implant selection, capsular contracture, inability of soft tissues to support the implant, or any combination. Most malpositions are preventable. Inferior displacement is common and may create a double-bubble or bottomed-out look; medial or lateral displacement often follows overdissection; superior displacement may follow underdissection or capsular contracture. Rotation applies only to shaped devices. In core studies, malposition occurred in 4.7% to 6.8% of primary augmentations and 6.0% to 9.1% of revisions within ten years; it was the second most common reason for revision after capsular contracture. Early or late occurrence depends on surgical technique and healing.

Anatomically, bottoming out can happen in three ways: the skin envelope stretches too much, the breast cone shifts too low over a fixed crease, or the inframammary crease itself descends . It may also reflect glandular ptosis worsened by implant weight, or dropping of the inframammary fold . After surgery, tissue can redistribute from the upper to lower pole during the first year, and heavy lower-pole bulk can restretch skin . Planning errors, such as leaving too much lower tissue or over-dissecting the lower pole, can contribute . Assessment should consider skin, tissue position, crease support and implant weight before any revision is discussed.

Symmastia means the breasts unite medially, sometimes with only a small bridge and sometimes total union. After augmentation, it is usually acquired: medial dissection can release the midline sternal skin attachment, and the implant cavities may unite (real symmastia) or remain separate (pseudo-symmastia). Congenital symmastia is rare, with weblike soft tissue crossing the sternum. Its cause is not fully understood, and diagnosis is made by inspection. It can appear immediately or days to weeks after augmentation. More cases have been reported after under-muscle augmentation, but it has also been described after under-breast-tissue procedures. Some patients have associated chest wall skeletal deformities or large implants, though these are associations, not proof of cause.

It is not one single problem. Evidence describes breast tissue drooping over a more superiorly placed implant, inadequate release or tightening of the lower breast fold, and muscle adhesions where the implant was placed partly under muscle and partly under breast tissue. In one described case, the implant appeared to slip beneath the native fold. Because these factors can overlap, correction may involve release, repositioning or resizing the implant, breast-lift revision, or changing the implant pocket, depending on examination. Correction can be difficult and results are not guaranteed. One described case also had a transverse crease across the inferior pole and animation with muscle movement.

Rippling means visible or palpable waves or folds from the implant through the skin. It may start when the capsule around the implant becomes smaller than the implant surface, often with capsular contracture, or when an implant is too large for its pocket. Saline implants can ripple more when underfilled, and less cohesive gel ripples more than cohesive gel. Gravity can pull the implant downward, while thin skin and subcutaneous coverage make any fold more noticeable. Good tissue padding lowers risk, but no implant fully compensates for inadequate coverage. Implant size and pocket fit also matter. These factors often overlap, so assessment matters.

Rippling means visible or palpable folds in the implant shell. It often shows when standing and may shift when lying down. It is more likely with thin skin or soft-tissue coverage, inadequate implant volume, bottoming out, or too much implant movement. Underfilled saline implants ripple more than gel-filled implants, and gel-filled more than cohesive gel; textured shells may ripple slightly less than smooth ones. Correction is complex and may include changing implant size or style, adjusting the pocket, fat grafting to thicken coverage, or using supportive material in selected thin patients. No implant can fully compensate for inadequate tissue coverage, and some deformities are largely uncorrectable.

Palpability means the implant can be felt through breast tissue. It is influenced by tissue quality, device characteristics and surgical technique, including how much tissue covers the implant. Placement behind breast tissue, muscle or fascia and incision choice vary by patient. A thinner tissue layer may make the implant easier to feel, while careful planning aims to optimize coverage. Implant type and tissue thickness also matter. There is no significant difference in how much you might feel your implants. The surgeon weighs these factors alongside your anatomy and preferences, and no surgeon can guarantee you will not feel them. Implant placement and tissue coverage are discussed before surgery to help set realistic expectations.

Reported saline-implant breast pain rates are 5–16% at 3 years and 7–17% at 5 years, and pain can increase over time. Pain may result from surgical trauma, improper implant size or placement, or surgical technique. It can also relate to capsular contracture, where scar tissue around the implant tightens, implant migration, pressure effects, or nerve irritation from tissue expansion. In reconstructive settings, implants may contribute to chronic pain through nerve compression or ischemia, or capsule contracture. Sensory changes are often temporary but can be permanent in up to 15% of patients. Persistent pain is not always implant-related; infection, hematoma, or other causes may also need assessment.

Infection may occur early, often within six weeks, from bacteria introduced during surgery, or later from host factors such as reduced immunity. Sources can include skin lesions, nipple discharge, cysts, contaminated devices, improper implant handling or operating-room contamination. Risk is higher with conditions such as obesity, diabetes, smoking, low haemoglobin, reconstruction after mastectomy, axillary dissection, chemotherapy or radiotherapy. Superficial wound infections are usually treated with drainage, local care and antibiotics; deeper infection may require implant removal, then reinsertion once tissue is soft and supple. Strict sterile technique and antibiotics reduce but cannot eliminate this risk, and infection is described as the most dangerous early event after augmentation.

Retained infected implants can lead to exposure with extrusion, capsular contracture, or even toxic shock syndrome. Once gross purulence forms, open drainage with thorough irrigation and implant removal is the treatment of choice. Some reports describe salvage of 16 of 29 infected implants by draining the pocket and giving intravenous antibiotics. Superficial wound infections are usually treated with drainage, local wound care and antibiotics, but infection can spread to underlying tissue and necessitate removal. After infection is treated and breast tissue is soft and supple, implants can be reinserted. Infection can have long-term sequelae on lactation because of removal and reinsertion, and reinsertion carries surgical risks.

Hematomas usually occur within the first 6 to 12 hours after surgery and may be triggered by coughing, straining or sudden arm movement. Small bleeding may be observed, but a large hematoma should be surgically evacuated. Because periprosthetic hematoma has been linked to capsular contracture, careful control of bleeding during surgery matters. Avoiding aspirin, NSAIDs and vitamin E for at least one week before surgery may reduce risk. Reported hematoma rates vary by study, from under 2% to 2.6-6.6% for primary augmentation. A seroma, a fluid collection, is a different and usually rarer early finding. Prompt assessment matters because an untreated hematoma can lead to tissue ischemia.

Fluid accumulates in the surgical space because of hydrostatic pressure from vascular and lymphatic vessels; with inflammation it may become protein-rich exudate. A seroma usually appears on the second or third postoperative day and is diagnosed with ultrasound. Late presentations may cause fluid sensation, pressure, firmness, or drainage from an open wound; without infection, fluid ranges from clear yellow serous to darker serosanguinous. Seroma formation is predictable and usually resolves without treatment. Aspiration is done only if the seroma is large and discrete enough to avoid the implant; it is performed through the lateral breast, not the incision, and repeated serially until resolution. Ultrasound-assisted drainage is reasonable, though cost may matter.

After surgery, some change in nipple sensation is not unusual, and for most patients sensation returns toward normal over several months. A larger implant may increase the chance of stretching the nerve enough to reduce feeling. Armpit incisions can cause small numb areas on the inner upper arm. Studies report a 15 to 49 percent change in nipple sensation, with larger implants linked to greater loss; whether implant placement changes this is unclear. Sensation is usually not permanently affected, although increasing implant size may diminish it. Permanent loss may occur occasionally. Numb skin often resolves completely after several months but may be permanent.

Changes are believed to come from traction, bruising or cutting of the nerves supplying nipple sensation. An incision around the areola is generally linked with the highest rate of change, while an armpit incision has a significantly lower rate. Large implants pressing sideways on these nerves or aggressive dissection may increase numbness. Augmentation with a lift involves more tissue disruption, so patients should be counselled about sensation changes and possible breastfeeding difficulty. Temporary changes may follow swelling; temporary numbness is occasionally reported after simple augmentation and may sometimes be avoided if the fourth and fifth intercostal nerves are preserved, though anatomy varies. Insufficient lactation may follow mastopexy, with or without augmentation, from scar tissue and interrupted ducts.

Scars are expected where incisions are made, and their appearance varies by incision site, skin quality, tension and healing. Combined augmentation with lifting increases tension and can worsen scarring or wound-edge problems. Some people are prone to wide or raised scars, and this may not be known until after surgery. Scar position matters too; an inframammary scar should sit near, not in, the crease to avoid irritation. Implant size and tissue support also influence stretching and long-term scar quality. Postbariatric patients may have increased wound-healing problems, including poor scarring, and large implants can put tension on skin closure. No outcome is guaranteed, and individual healing varies. Dr. Purohit can discuss these factors during consultation.

Most women have some breast asymmetry. After augmentation, unevenness may come from pre-existing differences, pocket dissection or implant positioning errors, saline underfilling or overfilling, implant migration from too large an implant or pocket, trauma, tissue atrophy from steroids, or incorrect pectoralis release. A unilateral implant can make breasts look more different because the smaller breast is often less droopy with a higher nipple. Mild to moderate differences under 90 to 120 cc may suit bilateral asymmetric implants. Implants may be placed behind breast tissue or muscle, and incision position varies by breast characteristics and preference. During consultation, the surgeon evaluates the most appropriate method.

In the first six months, skin stretches to accommodate the implant and a capsule forms around it. The degree of stretch and capsular tightening varies and is not fully predictable; one capsule may tighten more than the other. Over time, implant pressure and tissue aging can contribute to excessive skin stretch, thinning of tissue under the skin, shrinkage of breast gland tissue or chest-wall pressure changes. These effects depend on implant size, projection, placement and your genetics, hormones and tissue quality. Implant and tissue forces interact continuously, and tissues usually become thinner and more compliant with age. Capsular tightening and skin stretch are inversely related. Most negative effects are not apparent in the first one to two years.

Skin quality, thickness and elasticity affect how well breast skin supports an implant over time. Thin, inelastic skin with stretch marks may not support added volume well, and normal postoperative stretching can worsen shape changes. After surgery, breast skin may stretch more in many patients. Thin or stretchy tissues may increase visible rippling or excessive lower-breast stretching, regardless of implant choice. Wide breasts with stretchy skin and a long nipple-to-fold distance may need more volume, increasing future stretching risk. Careful, tissue-based implant selection aims to avoid overprojection, excessive stretching, tissue thinning and parenchymal atrophy. If skin is thin and stretched too much, scars may widen. Neither you nor your surgeon can change your tissue characteristics.

Implants need padding from fat and breast tissue. With good coverage, placement behind breast tissue can look natural, but many patients have limited padding and may do better behind the chest muscle. Even then, muscle does not cover the outer edge, so edge visibility can remain, especially with capsular contracture. Superficial placement may make implants perceptible immediately or after two to three years as tissue loosens. Deeper placement generally camouflages better, yet it can bring animation or superior displacement. Implant choice and size should respect tissue limits. In very lean patients, such as body builders, little fat means the implant can show through skin. Good tissue coverage and skin quality also help camouflage.

The implant sits on the chest wall platform, so pre-existing asymmetry, rib prominence or sternum shape can affect breast shape after augmentation. Chest wall length and breadth vary greatly, and implant diameter should be matched carefully; a very wide implant in a narrow chest may create excessive lateral fullness. The implant is placed behind breast tissue or pectoralis major to push the breast forward; breast tissue compression occurs, while rib distortion is rare. Chest wall asymmetry can significantly affect the final breast shape, so your surgeon should observe and discuss it before surgery and may adjust implant size or placement, and point out any limitations this may place on the overall result.

Any procedure requiring general anaesthesia increases the risk of blood clots forming in the legs. Such clots can dislodge and move to the lungs, causing shortness of breath and strain on the heart, and they can potentially be fatal. One source notes clots can develop in leg veins during surgery and possibly lead to pulmonary embolus in about 1 in 10,000 cases, with inflatable boots used on the legs during surgery to help minimize this chance. This is a rare but serious possibility, so symptoms should not be ignored. If you experience shortness of breath, chest pain or palpitations after surgery, seek medical advice immediately.

Breast augmentation is major surgery, so anesthesia is part of the overall risk discussion. Both local and general anesthesia involve risk, though generally small. A collapsed lung can occur while creating the implant pocket if a small tear occurs in the thin tissue between the ribs, and treatment may require a chest tube. Clots can develop in leg veins during surgery and may lead to pulmonary embolus, estimated at 1 in 10,000; inflatable boots are used on the legs to help minimize that chance. The estimated risk of death from anesthesia is one in 250,000. These figures come from an informed-consent sample and should be discussed individually.